Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer.
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) harboring BIM deletion-polymorphism (BIM deletion) have poor responses to EGFR-tyrosine kinase inhibitor (TKIs). Mechanistically, the BIM deletion induces preferential splicing of the non-functional exon 3-containing isoform over the functional exon 4-containing isoform, impairing TKI-induced, BIM-dependent apoptosis. Histone deacetylase inhibitor, vorinostat, re-sensitizes BIM deletion-containing NSCLC cells to EGFR-TKIs. In this study, we determined the safety of vorinostat-gefitinib combination and evaluated pharmacodynamic biomarkers of vorinostat activity. Patients with EGFR-mutated NSCLC with the BIM deletion, pre-treated with EGFR-TKI and chemotherapy, were recruited. Vorinostat (200, 300, 400 mg) was administered daily on days 1-7, and gefitinib 250 mg was administered daily on days 1-14. Vorinostat doses were escalated based on a conventional 3 + 3 design. Pharmacodynamic markers were measured using peripheral blood mononuclear cells (PBMCs) collected at baseline and 4 h after vorinostat administration on day 2 in cycle 1. No dose-limiting toxicities (DLTs) were observed in 12 patients. We determined 400 mg vorinostat as the recommended phase 2 dose (RDP2). Median progression-free survival was 5.2 months (95% CI 1.4-15.7). The disease control rate at 6 weeks was 83.3% (10/12). Vorinostat preferentially induced BIM mRNA containing exon 4 over mRNA containing exon 3, acetylated histone H3 protein, and pro-apoptotic BIMEL protein in 11/11, 10/11, and 5/11 patients, respectively. These data indicate that the RDP2 was 400 mg vorinostat combined with gefitinib in BIM deletion/EGFR mutation double-positive NSCLC. The BIM mRNA exon3/exon4 ratio in PBMCs may be a useful pharmacodynamic marker for treatment.